Why the study?
The molecular mechanisms underlying phenotypic variation in circulating IL-6 levels and their relation to cardiovascular disease remain less understood.
Observational (n=4,400)
Answers are grounded in this paper and cite their sources.
The study identifies novel DNA methylation sites associated with circulating IL-6 levels, providing potential epigenetic mechanisms and therapeutic targets for cardiovascular disease pathophysiology.
BACKGROUND AND AIMS: Cardiovascular disease (CVD) is one of the leading causes of morbidity and mortality worldwide, yet the underlying molecular mechanisms remain less understood. Chronic low-grade inflammation is a complex immune response contributing to the pathophysiology of cardiovascular disease. This response is signaled in part by interleukin-6 (IL-6), a pleiotropic, pro-inflammatory cytokine. Phenotypic variance in circulating IL-6 level may be explained in part by DNA methylation which is increasingly being associated with cardiovascular effects. METHODS: In this study we evaluated methylated DNA (CpG sites) associated with blood IL-6 levels across ∼4,400 ancestrally diverse individuals (81 % self-reported White; 9 % Black or African American, 8 % Hispanic or Latino/a, and 2 % Chinese American). RESULTS: We identified 178 CpG sites associated with IL-6 (p<0.05/∼395,000). Among the sites, cg04437762 is located within the transcription unit of IL6R, a current therapeutic target for inflammatory disease, and cg26692003 and cg00464927 were significant for IL6 and IL6ST trans-CpG-gene transcripts. Functional gene expression downstream of methylation identified cellular response to IL-6 and B-cell regulation and activation pathways. Four genes were linked with both a genetic component of cardiovascular disease and an IL-6 associated CpG site. Three CpG sites identified through Mendelian randomization analyses supported inference of a causal effect on IL-6 levels, including the LYN gene that regulates immune cell signaling and has been previously associated with atherosclerosis. CONCLUSIONS: Overall, we identified several novel IL-6-CpG sites and downstream pathways affected by methylation. Follow-up functional studies including the regulation of IL-6 would complement current knowledge of CVD pathophysiology and potential therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Lundin et al. (2025) conducted an observational in Inflammation and Cardiovascular Disease (n=4,400). DNA methylation (CpG sites) was evaluated on Association of methylated DNA with blood IL-6 levels (p=<0.05/∼395,000).
Synapse has enriched 10 related papers. Consider them for comparative context: